CJC-1295 + Ipamorelin Stack: The Standard GH Peptide Protocol Explained

CJC-1295 + Ipamorelin Stack: The Standard GH Peptide Protocol Explained

Key Takeaways:

• CJC-1295 and ipamorelin target different GH release pathways (GHRH receptor and ghrelin receptor respectively) and produce synergistic GH output when combined.
• The combination is the most widely used injectable GH secretagogue protocol in community and some clinical contexts.
• Peak GH output from the stack is significantly higher than either compound used alone.
• Results are gradual: improved sleep is typically the first effect (weeks 1-2), body composition changes appear over 8-16 weeks.
• This stack does not produce GLP-1-class weight loss. It produces slow body recomposition.

Important: This is not medical advice. CJC-1295 and ipamorelin are research peptides, not FDA-approved medications. The content below summarizes scientific rationale, published research, and community-reported protocols for educational purposes only. Consult a qualified healthcare provider before using any peptide. See our full medical disclaimer.

---

Why this stack exists

The CJC-1295 and ipamorelin combination is not arbitrary. It is built on a mechanistic rationale that has clear scientific grounding.

The pituitary gland releases growth hormone in response to two primary signals from the hypothalamus:

1. Growth hormone-releasing hormone (GHRH) binds the GHRH receptor and promotes GH synthesis and release
2. Ghrelin (and ghrelin mimetics) bind the ghrelin receptor (GHS-R1a) and trigger a separate GH release pathway

These two pathways are distinct at the receptor level but converge on the same outcome: GH secretion from pituitary somatotroph cells. When both pathways are activated simultaneously, the resulting GH pulse is substantially larger than what either signal produces alone. This synergy is documented in the literature and is the foundational reason this specific combination was developed.

CJC-1295 is a GHRH analog. It stimulates the GHRH receptor. Ipamorelin is a ghrelin receptor agonist. It stimulates GHS-R1a. Stacking them hits both pathways at the same time. For a broader view of how these compounds fit within their categories, see our growth hormone secretagogues guide and our individual guides on ipamorelin and CJC-1295.

The synergy: what the research shows

The synergistic interaction between GHRH-class and GHRP-class compounds is established in research literature. Early studies on GHRH + GHRP-6 combination (before ipamorelin was available) demonstrated that co-administration produced GH pulses 3-5 times larger than either compound administered alone (PMID: 7928953).

The mechanism at the cellular level involves two distinct intracellular signaling cascades. GHRH activates the cAMP/PKA pathway, which primes somatotroph cells for GH release. GHRH receptor stimulation also increases calcium sensitivity in these cells. Ghrelin receptor activation independently raises intracellular calcium directly through the PLC/IP3 pathway. Activating both pathways together uses different cellular machinery simultaneously, producing a larger response than either pathway alone.

This is why the combination has become standard. It is not marketing or habit. There is a clear mechanistic and experimental basis for it.

CJC-1295: DAC or no-DAC in the stack?

This is the most common technical question about the stack protocol. The two variants of CJC-1295 behave differently in the context of a timed GH pulse strategy.

CJC-1295 without DAC (Mod GRF 1-29): Half-life of approximately 30 minutes. When co-injected with ipamorelin, it activates the GHRH receptor and produces an amplified GH pulse within the same short time window as the ipamorelin pulse. The result is a discrete, pulsatile GH release that more closely resembles natural GH physiology.

CJC-1295 with DAC: Half-life of 6-8 days. Creates sustained GHRH receptor stimulation. The GH profile becomes more of a continuous elevation rather than a discrete pulse. When combined with ipamorelin (which still produces individual pulses), the result is a higher GH baseline with pulses layered on top.

In practice, CJC-1295 without DAC is more commonly used in the pulse-based stack because it maintains the pulsatile character of the combined GH release, which many practitioners consider more physiologically appropriate. CJC-1295 with DAC allows for less frequent injection (once weekly instead of 2-3 times daily), which suits some users who prefer convenience over pulse fidelity.

For the protocols below, we describe the no-DAC version as the default, which is the more common community choice.

The standard protocol

Doses

Ipamorelin: 100-300 mcg per injection

CJC-1295 without DAC: 100-200 mcg per injection (often matched to ipamorelin dose)

Doses are co-injected in the same syringe. They are chemically compatible and mixing them does not cause degradation.

Injection frequency

Standard protocol: 2 times daily

• Injection 1: Before sleep (the most important injection, targeting the natural nocturnal GH pulse)
• Injection 2: Pre-workout or early morning in a fasted state

More aggressive protocol: 3 times daily

• Injection 1: Morning, fasted
• Injection 2: Pre-workout (or mid-afternoon, fasted)
• Injection 3: Before sleep

The 3-times-daily protocol produces higher total daily GH output. The benefit over twice-daily dosing is debated in community discussions. The incremental GH gain from the third injection may not justify the additional cost and injection burden for most users.

Once-daily protocol: Some users inject only once daily before sleep. This is lower output than twice daily but simpler. For users primarily targeting sleep improvement and modest body composition effects rather than maximum GH output, once daily is a reasonable starting point.

Timing relative to meals

GH release is blunted by insulin. Elevated blood glucose and insulin suppress natural GH secretion, and the same suppression applies to GH secretagogue-stimulated pulses. The practical guideline:

• Administer at least 2 hours after a meal
• Do not eat for at least 30-60 minutes after injection (to allow the GH pulse to complete without insulin interference)
• Sleep injections are inherently timed well, assuming no late-night snacking

Carbohydrates and fats raise insulin most significantly. Protein raises insulin too, though less dramatically. For the cleanest GH pulse, a fully fasted state is optimal, but 2+ hours post-meal is a practical minimum.

Cycle structure

Cycle length: 8-12 weeks on, followed by a 4-8 week break

The break rationale is to prevent potential GHS-R1a receptor downregulation from continuous ipamorelin stimulation, and to allow natural GH secretion patterns to normalize. The evidence base for specific cycle lengths is based primarily on community practice rather than controlled human trials.

Ongoing use: Some practitioners use GH secretagogue protocols more continuously, particularly in anti-aging contexts, with periodic monitoring of IGF-1 levels to ensure they remain within an appropriate range.

What to expect: realistic timeline

Weeks 1-2

Sleep quality is the most commonly reported first effect. Users describe deeper sleep, more vivid dreams, and feeling more rested upon waking. This aligns with the established relationship between GH and slow-wave sleep architecture. GH secretion is highest during slow-wave sleep, and amplifying it tends to also improve the quality of the sleep itself.

Some users notice a slight increase in fatigue or lethargy in the first week as the body adjusts to elevated GH. This typically resolves.

Weeks 3-6

Water retention becomes apparent. GH elevation increases extracellular fluid. Some users notice puffiness in the face, hands, or feet. This is the most commonly misinterpreted effect. Body weight may increase slightly during this period even though fat tissue has not increased. This early weight gain is fluid, not fat.

Recovery from training may improve. Some users report less soreness and faster recovery from workouts. The mechanism is plausible: GH and IGF-1 both support tissue repair and protein synthesis.

Appetite. Unlike GHRP-6 or MK-677, ipamorelin does not typically cause significant appetite stimulation. Most users report minimal to no hunger increase.

Weeks 6-12

Gradual body composition changes become visible. The changes are slow and cumulative. Users typically describe:

• Mild reduction in visible fat, often noted first in the abdominal area
• Muscle fullness and maintenance of lean mass, even on a slight caloric deficit
• Skin may appear slightly improved (consistent with collagen synthesis effects of IGF-1)

What this does not look like: The before-and-after photos sometimes associated with this stack in marketing contexts are typically either the result of much longer use, much higher doses, combined with other compounds, or edited. A 12-week course of CJC-1295 and ipamorelin alone produces modest, real changes, not dramatic transformations.

Beyond 12 weeks

Body composition changes continue to accumulate gradually. Users who continue beyond a single cycle (with appropriate breaks) report the most meaningful long-term effects on body composition, though this is based on community experience rather than controlled data.

Comparison to other GH approaches

vs GHRP-2 or GHRP-6 stacked with CJC-1295: Swapping ipamorelin for GHRP-2 or GHRP-6 would produce a larger GH pulse (particularly GHRP-2) but introduce cortisol and prolactin elevation (both compounds) and appetite stimulation (GHRP-6 especially). For most body composition goals, ipamorelin's cleaner profile makes it the preferred GHRP. See our GHRP-2 vs GHRP-6 comparison.

vs MK-677 alone: MK-677 provides oral convenience and excellent sleep data but causes more significant insulin resistance and appetite stimulation. The injectable stack is generally considered to produce more pulsatile, physiological GH release. For users who cannot or will not inject, MK-677 is the alternative to evaluate. See our MK-677 guide.

vs tesamorelin: Tesamorelin is the FDA-approved GHRH analog with the strongest clinical evidence for visceral fat reduction. It is more expensive and harder to obtain off-label. The CJC-1295 + ipamorelin stack is the more accessible alternative for people seeking similar effects without a clinical indication. See our tesamorelin fat loss guide.

vs exogenous HGH: The stack stimulates natural GH production and preserves pituitary feedback regulation. Exogenous HGH bypasses these mechanisms. The stack is generally considered the lower-risk approach for body composition at physiological GH levels. See our GH secretagogues vs HGH comparison.

vs GLP-1 receptor agonists: These are not comparable approaches. GLP-1 drugs (semaglutide, tirzepatide) produce appetite suppression and direct caloric reduction, leading to substantial weight loss. The CJC-1295 + ipamorelin stack produces body recomposition through GH physiology. For dedicated weight loss, GLP-1 drugs have a vastly superior evidence base. For someone who wants body recomposition with maintained or improved lean mass, GH secretagogues address a different set of mechanisms. Also see our earlier post on CJC-1295 ipamorelin weight loss results for a detailed breakdown of realistic outcomes.

Side effects of the combined stack

Side effects of the stack are generally the sum of each compound's individual effects, without new unique interactions introduced by the combination.

Water retention. The most common. GH elevation drives extracellular fluid increases. Usually manageable; dose reduction helps.

Tingling or numbness. Carpal tunnel-like symptoms, fluid-related. Typically mild and dose-dependent.

Injection site reactions. Redness or irritation at the injection site. More common with impure compounds or poor injection technique.

Headaches. Mild headaches are reported, particularly early in a cycle.

Cortisol and prolactin. Ipamorelin does not significantly elevate these hormones. CJC-1295 as a GHRH analog does not either. This is an advantage of the ipamorelin choice over GHRP-2 or GHRP-6.

Hunger. Ipamorelin's hunger effect is mild. GHRH analogs do not stimulate appetite. Users report minimal to no increase in hunger with this specific stack.

IGF-1 elevation. Sustained IGF-1 elevation carries the long-term cancer risk associations noted for all GH secretagogues. This applies to the stack as well.

Practical considerations

Reconstitution and storage: Both peptides arrive as lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. Reconstituted solution should be stored refrigerated (2-8 degrees Celsius) and used within 28-30 days. Mixing both peptides in the same syringe requires calculating volumes from each vial's concentration.

Sourcing quality: The quality of research compound sourcing varies enormously. Certificate of analysis (CoA) from a third-party lab is the minimum standard for evaluating source quality. Impure or mislabeled compounds are a real issue in this market.

Physician monitoring: If possible, working with a physician who can order baseline and periodic IGF-1 levels is preferable to blind self-administration. IGF-1 monitoring allows dose adjustment to keep levels within physiologically normal ranges.

FAQ

Can beginners use the CJC-1295 + ipamorelin stack? It is accessible compared to some other protocols (no anabolic steroids, no direct hormone replacement), but it is not without risk. Anyone starting with peptide protocols should research thoroughly, start at the lower end of dose ranges, and ideally do so with physician oversight.

Is the stack more effective for men or women? The research does not support a clear sex-based difference in GH secretagogue response. Women naturally have higher GH pulsatility than men, so baseline differences exist, but both sexes respond to GHRH and GHRP stimulation.

What if I only inject once a day? You will get less total GH output than with twice-daily dosing, but the nocturnal pulse targeted by the sleep injection is the most physiologically significant. Once-daily before sleep is a reasonable starting point for new users.

Do I need to taper off at the end of a cycle? Unlike anabolic steroids, GH secretagogues do not require a post-cycle therapy (PCT) protocol. The pituitary's natural GH production recovers on its own when the compounds are stopped because natural GH production was stimulated, not replaced.

Can this stack be combined with GLP-1 medications? These work through entirely different mechanisms and can theoretically coexist. Some users combine GH secretagogues with GLP-1 medications. The interaction is not well-studied clinically. Anyone on prescription medications should discuss additions with their prescribing physician.

---

Sources

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
2. Jetté L, et al. hGH-releasing peptide-2 stimulates GH secretion. J Clin Endocrinol Metab. 2005;90(11):6031-6037. PMID: 16352683
3. Popovic V, et al. Synergistic effect of growth hormone-releasing hormone and GHRP-6 on GH secretion in man. J Endocrinol Invest. 1994. PMID: 7928953
4. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28586565
5. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16984982

---

This content is for educational purposes only and does not constitute medical advice. CJC-1295 and ipamorelin are research compounds not approved for human use. Consult a licensed healthcare provider before using any peptide. Full disclaimer. For a dedicated look at /peptide-stacks and how they compare across categories, see our peptide stacks guide.